Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
AKYA

AKYA - Akoya Biosciences, Inc. Stock Price, Fair Value and News

$1.29 
Market Closed

Price Targets

AKYA Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

AKYA Price Action

Last 7 days

-5.1%

Last 30 days

-2.3%

Last 90 days

4.0%

Trailing 12 Months

-42.7%

AKYA RSI Chart

AKYA Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

AKYA Valuation

Market Cap

64.3M

Price/Earnings (Trailing)

-1.35

Price/Sales (Trailing)

0.8

EV/EBITDA

-1.42

Price/Free Cashflow

-1.99

AKYA Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

AKYA Fundamentals

AKYA Revenue

Revenue (TTM)

80.0M

AKYA Earnings

Earnings (TTM)

-47.5M

AKYA Profitability

Operating Margin

61.74%

EBT Margin

-59.28%

Return on Equity

807.15%

Return on Assets

-42.2%

Free Cashflow Yield

-50.27%

AKYA Investor Care

Shares Dilution (1Y)

0.99%

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
202580.0M000
202493.6M93.2M86.8M81.7M
202379.4M85.0M91.4M96.6M
202259.6M64.4M69.8M74.9M
202143.6M48.1M51.7M54.9M
202000042.4M
Get all data in R, Python etc through our Historical Stock Data APIs

About Akoya Biosciences, Inc.

AKYA
Akoya Biosciences, Inc., a life sciences technology company, provides spatial biology solutions focused on transforming discovery and clinical research in North America, the Asia Pacific, Europe, the Middle East, and Africa. The company offers PhenoCycler instrument, a compact bench-top fluidics system that integrates with a companion microscope to automate image acquisition; and PhenoImager platform that enables researchers to visualize, analyze, quantify, and phenotype cells in situ, in fresh frozen or FFPE tissue sections, and tissue microarrays utilizing an automated and high-throughput workflow. It also provides PhenoCycler and PhenoImager reagents; and biopharma services. In addition, the company offers analysis software partnerships ecosystem; inForm Tissue, an automated image analysis software package for accurately visualizing and quantifying biomarkers in tissue sections; Phenoptr, which provides functions that consolidate and analyze output tables created by inForm software; and phenoptrReports, a software that generates shareable reports and visualizations based on the phenoptr output in an intuitive front-end GUI. The company was incorporated in 2015 and is headquartered in Marlborough, Massachusetts.
 CEO
 WEBSITEakoyabio.com
 SECTORHealthcare
 INDUSTRYMedical Instruments & Supplies
 EMPLOYEES369

Akoya Biosciences, Inc. Frequently Asked Questions

AKYA is the stock ticker symbol of Akoya Biosciences, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

As of Wed Jul 16 2025, market cap of Akoya Biosciences, Inc. is 64.34 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

You can check AKYA's fair value in chart for subscribers.

The fair value guage provides a quick view whether AKYA is over valued or under valued. Whether Akoya Biosciences, Inc. is cheap or expensive depends on the assumptions which impact Akoya Biosciences, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for AKYA.

As of Wed Jul 16 2025, AKYA's PE ratio (Price to Earnings) is -1.35 and Price to Sales (PS) ratio is 0.8. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. AKYA PE ratio will change depending on the future growth rate expectations of investors.